胰高血糖素样肽1影响动脉粥样硬化的研究进展  

Review of glucagon-like peptide-1 in the management of atherosclerosis

作　　者：李波[1] 陈韵岱[1] LI Bo CHEN Yun-Dai(Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China)

机构地区：[1]中国人民解放军总医院心血管内科,北京市100853

出　　处：《中国动脉硬化杂志》2017年第4期427-432,共6页Chinese Journal of Arteriosclerosis

摘　　要：胰高血糖素样肽1(GLP-1)是一种新型治疗2型糖尿病肠促胰液素,它可以在进食后血糖升高而刺激肠道分泌进而控制血糖。越来越多的研究表明,GLP-1可直接作用于心血管系统,例如可以影响内皮功能、炎症反应、血压、血脂代谢等。本文将对GLP-1类药物包括GLP-1类似物和二肽激肽酶4抑制剂影响动脉粥样硬化以及其潜在的机制进行综述。Glucagon-like peptide-1 （GLP-1） is an incretin hormone whose glucose-dependent insulinotropic actions have been regulated as a novel therapy for glycemic control in diabetes. Emerging evidence indicates that GLP-1 exerts direct effects on specific aspects of cardiovascular disease, such as endothelial dysfunction, inflammation, blood pressure and lipid metabolism. This review will focus on the effects of incretin therapies, including GLP-1 analogs and dipeptidyl peptidase （DPP）-4 inhibitors, on the atherosclerosis disease, and will discuss the potential mechanisms underlying these effects.

关 键 词：胰高血糖素样肽1 胰高血糖素样肽1受体激动剂 二肽激肽酶4抑制剂 动脉粥样硬化 

分 类 号：R363[医药卫生—病理学]